Vanguard Group Inc boosted its holdings in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 450,456 shares of the biotechnology company’s stock after acquiring an additional 21,000 shares during the period. Vanguard Group Inc owned about 2.36% of Eiger Biopharmaceuticals worth $5,406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP bought a new position in Eiger Biopharmaceuticals during the 3rd quarter worth about $194,000. Tocqueville Asset Management L.P. bought a new position in Eiger Biopharmaceuticals during the 3rd quarter worth about $203,000. Bank of New York Mellon Corp boosted its holdings in shares of Eiger Biopharmaceuticals by 36.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 20,412 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 5,492 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Eiger Biopharmaceuticals by 38.0% in the 2nd quarter. Northern Trust Corp now owns 40,552 shares of the biotechnology company’s stock valued at $495,000 after buying an additional 11,176 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Eiger Biopharmaceuticals in the 3rd quarter valued at about $619,000. Institutional investors own 50.65% of the company’s stock.
In related news, Director Eldon C. Mayer III acquired 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 28th. The stock was purchased at an average cost of $10.07 per share, with a total value of $60,420.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $75,525. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Eldon C. Mayer III acquired 7,500 shares of the firm’s stock in a transaction that occurred on Monday, November 26th. The stock was bought at an average cost of $9.75 per share, with a total value of $73,125.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $73,125. The disclosure for this purchase can be found here. Insiders purchased a total of 23,727 shares of company stock valued at $242,953 over the last ninety days. 7.90% of the stock is currently owned by insiders.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($1.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.43). As a group, research analysts anticipate that Eiger Biopharmaceuticals Inc will post -3.46 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Tuesday, February 5th. Robert W. Baird assumed coverage on shares of Eiger Biopharmaceuticals in a report on Monday, January 28th. They issued an “outperform” rating and a $47.00 price target on the stock. Finally, ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $33.38.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Read More: Relative Strength Index
Want to see what other hedge funds are holding EIGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eiger Biopharmaceuticals Inc (NASDAQ:EIGR).
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.